|
|
|
|
| LEADER |
01490nam a2200349 u 4500 |
| 001 |
EB001999925 |
| 003 |
EBX01000000000000001162826 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a CADTH Canadian Drug Expert Committee recommendation: Dupilumab (Dupixent -- Sanofi-Aventis Canada Inc.)
|h Elektronische Ressource
|b indication: atopic dermatitis
|
| 246 |
3 |
1 |
|a Dupilumab (Dupixent -- Sanofi-Aventis Canada Inc.)
|
| 246 |
3 |
1 |
|a Drug reimbursement recommendation Dupilumab (Dupixent)
|
| 250 |
|
|
|a Final
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH
|c 2020, April 24, 2020
|
| 300 |
|
|
|a 1 PDF file (10 pages)
|
| 653 |
|
|
|a Insurance, Health, Reimbursement
|
| 653 |
|
|
|a Antibodies, Monoclonal, Humanized / economics
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Dermatitis, Atopic / drug therapy
|
| 653 |
|
|
|a Antibodies, Monoclonal, Humanized / therapeutic use
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 500 |
|
|
|a "This recommendation supersedes the CADTH Canadian Drug Expert Committee recommendation for this drug and indication dated June 27, 2018."
|
| 856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK564615
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 140
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 330
|